TIDMNFX
RNS Number : 3005B
Nuformix PLC
19 September 2018
Nuformix plc
Result of Annual General Meeting
The Annual General Meeting of Nuformix plc was held on 19(th)
September 2018 at 1.00pm, at the offices of Shakespeare Martineau
LLP, 60 Gracechurch Street, London, EC3V 0HR.
The Directors of the Company wish to announce that all the
resolutions were passed by the required majority. The results of
the voting by poll on the resolutions put to the meeting are listed
below.
Resolution Ordinary/ For* Against Total
Special votes
cast
No. of % No. of %
votes votes
To receive the annual
report and accounts
for the year ended
1 31 March 2018 Ordinary 141,656,903 100 0 0 141,656,903
To approve the Directors'
2 Remuneration Policy Ordinary 134,767,823 95.14 6,889,080 4.86 141,656,903
To approve the Annual
3 Report on Remuneration Ordinary 134,767,823 95.14 6,889,080 4.86 141,656,903
To re-appoint David
4 Tapolczay as a director Ordinary 141,656,903 100 0 0 141,656,903
To re-appoint Daniel
5 Gooding as a director Ordinary 134,767,823 95.14 6,889,080 4.86 141,656,903
To re-appoint Joanne
6 Holland as a director Ordinary 141,656,903 100 0 0 141,656,903
To re-appoint John
7 Lidgey as a director Ordinary 141,656,903 100 0 0 141,656,903
To re-appoint Kirk
Siderman-Wolter
8 as a director Ordinary 141,656,903 100 0 0 141,656,903
To re-Christopher
9 Blackwell as a director Ordinary 141,656,903 100 0 0 141,656,903
To re-appoint haysmacintyre
10 as auditor Ordinary 141,656,903 100 0 0 141,656,903
To authorise the
Directors to determine
11 the auditor's fees. Ordinary 134,767,823 95.14 6,889,080 4.86 141,656,903
To authorise the
Directors to allot
12 shares. Ordinary 134,767,823 95.14 6,889,080 4.86 141,656,903
To authorise the
Directors to disapply
13 pre-emption rights. Special 134,767,823 95.14 6,889,080 4.86 141,656,903
To authorise the
Company to purchase
14 its own shares. Special 134,767,823 95.14 6,889,080 4.86 141,656,903
To authorise calling
of a general meeting
on 14 clear days'
15 notice. Special 134,767,823 95.14 6,889,080 4.86 141,656,903
*The 'For' votes include those votes giving the Chairman
discretion.
A vote withheld is not a vote in law and is not counted in the
calculation of votes validly cast for or against a resolution.
The Company's issued share capital is 460,750,000 ordinary
shares of 0.1p each.
Copies of the resolutions passed as special resolutions at the
AGM will shortly be available for inspection at the National
Storage Mechanism, which is located at:
http://www.morningstar.co.uk/uk/nsm.
19 September 2018
For further information please contact:
Nuformix plc
Dr Dan Gooding, Chief Executive Officer +44 (0)1223 423667
Gable Communications Ltd
John Bick / Justine James +44 (0)20 7193 7463
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio containing a range of
granted patents covering cocrystal forms of five small molecule
drugs. Nuformix is targeting high-value unmet needs with its lead
programmes in oncology supportive care: NXP001 and fibrosis:
NXP002.
Nuformix was established in Cambridge in 2009 and has invested
into pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities. Nuformix plc shares are
traded on the London Stock Exchange's Official List under the
ticker: NFX.L.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGXKLFFVKFXBBF
(END) Dow Jones Newswires
September 19, 2018 09:33 ET (13:33 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2023 to Apr 2024
